PHARMExcel welcomes the new MHRA (Medicines and Healthcare Products Regulatory Agency) Corporate Plan which sets out how it will keep patients safe while enabling access to innovative, safe and effective medical products over the coming three years.
The plan sets out the agency’s strategic priorities:
As a CRO with a focus in vaccines and immunotherapies and cell and gene therapies, PHARMExcel is pleased to note the mention of risk-proportionate regulations and priority regulatory pathways.
Yvanne Enever, CEO of PHARMExcel, praised the new plan saying “It’s imperative as new medical technologies are developed globally, we adapt our ways of working to remain relevant and ensure the UK continues to compete on the international stage, delivering high quality and scientifically valuable trials to improve human health.
I welcome seeing definitive changes to research management in the forthcoming months/years. I am also delighted the MHRA will continue to work closely with other regulators through collaborative groups such as the International Council for Harmonisation, the International Coalition of Medicines Regulatory Authorities and the International Medical Device Regulators Forum (IMDRF).”
Yvanne Enever, CEO of PHARMExcel
In year two the MHRA anticipate focusing on two important drug safety issues over two years and developing a business model to roll out across all medicines and vaccines to better minimise risks for all patients by understanding the role of genetics in adverse reactions.
PHARMExcel is an award-winning, full-service Contract Research Organisation (CRO) providing a flexible and innovative approach to clinical trial delivery. The company is recognised for its in-depth knowledge and experience of the clinical research environment, particularly in the UK, and has a network of regulatory and industry associates, allowing it to provide a global reach.
Media Contact
Katie Howe, Head of Marketing
E: katie.howe@pharmexcel-cro.com
T: +44 (0)20 3642 6654
